Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Investigational antiviral drug effectively treats Lassa virus infection in guinea pigs

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Researchers develop new genomic data set on Lassa virus

Researchers develop new genomic data set on Lassa virus

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

Investing in new hepatitis C therapies may have significant economic impact

Investing in new hepatitis C therapies may have significant economic impact

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Combination treatment effective for HCV genotype-1 mono-infected patients

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data supports use DAAs in patients with HCV recurrence following liver transplantation

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015